SubsidieMeestersRNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming
The RIPECROP project aims to enhance cancer immunotherapy by developing mRNA-based agents that boost cDC1 cells in tumors to improve anti-tumor T-cell crosspriming.
Projectdetails
Introduction
Cancer immunotherapy achieves unprecedented efficacy against a number of malignant diseases. Preclinical experiments in mouse models conclude that type-1 dendritic cells (cDC1) that present tumor antigens are an absolute requirement for most immunotherapy strategies to be efficacious, including those routinely applied to cancer patients at present.
Role of cDC1 Cells
cDC1 cells are specialized in redirecting engulfed cell-associated antigens to the class I MHC antigen-presentation pathway in the context of IL-12 production and co-stimulation, at least when cDC1 cells are in the presence of moieties denoting viral infection. Such phenomena are key to prime anti-tumor T lymphocytes through a mechanism known as crosspriming.
RIPECROP Project Overview
The RIPECROP project will test immunotherapy agents that enhance the numbers and performance of cDC1 in the tumor tissue microenvironment. The strategies will be based on mRNA constructs that will encode:
- Engineered forms of the cDC1 growth factor sFLT-3L
- Single-chain interleukin-12
- cDC1 specific chemoattractants
- Bispecific costimulatory ligands targeted to surface proteins of cDC1 cells
Therapeutic Agents and Delivery
The new therapeutic agents in the form of coding mRNAs will be expressed in vivo either intratumorally or using the mRNA-transferred liver as an internal “biofactory” to systemically produce the encoded proteins and their combinations.
Innovative Screening Methods
Innovative in-vivo screenings based on hydrodynamic gene transfer of the liver with various expression plasmids encoding heterodimerization systems will be performed to identify suitable new mRNA-based immunotherapeutic chimeric constructs to enhance antitumor T-cell crosspriming.
Conclusion
Overall, a novel mRNA-based toolbox will be studied both in terms of anti-tumor efficacy and regarding the mechanisms of action, in such a manner that crosspriming will become exploitable in combinatorial approaches for cancer immunotherapy.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 2.500.000 |
Tijdlijn
| Startdatum | 1-10-2024 |
| Einddatum | 30-9-2029 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMApenvoerder
- UNIVERSIDAD DE NAVARRA
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Polyclonal anti-tumor immunity by engineered human T cellsThis project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes. | ERC STG | € 1.812.500 | 2022 | Details |
Engineering B cells to fight cancerThis project aims to develop a novel cancer immunotherapy using engineered B cells to enhance anti-tumor responses through targeted gene integration and localized immune activation. | ERC COG | € 1.996.250 | 2022 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC POC | € 150.000 | 2023 | Details |
Neoantigen Identification with Dendritic Cell ReprogrammingThe NeoIDC project aims to revolutionize cancer immunotherapy by using cDC1 reprogramming to identify immunogenic neoantigens and TCRs for developing effective vaccines and adoptive T cell therapies. | ERC POC | € 150.000 | 2023 | Details |
Polyclonal anti-tumor immunity by engineered human T cells
This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.
Engineering B cells to fight cancer
This project aims to develop a novel cancer immunotherapy using engineered B cells to enhance anti-tumor responses through targeted gene integration and localized immune activation.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
Neoantigen Identification with Dendritic Cell Reprogramming
The NeoIDC project aims to revolutionize cancer immunotherapy by using cDC1 reprogramming to identify immunogenic neoantigens and TCRs for developing effective vaccines and adoptive T cell therapies.